

# INCYTE CORP

ISIN: US45337C1027

WKN: 45337C102

Asset Class: **Stock**

## Company



2024/05/21 22:00:00

Price

**57.40**

USD

Difference

**0.37%**(0.21)



## Contact Details

INCYTE CORP. Tel: +1-302-498-6700  
 -- Fax: +  
 1801 Augustine Cut-Off Web: <http://www.incyte.com>  
 19803 Wilmington E-mail: -

## Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	4,645,402,000		4,092,850,000		3,118,674,000	
<b>Common stock capital</b>		224,000		223,000		221,000
<b>Fixed assets</b>	2,176,919,000		1,790,696,000		1,855,056,000	
<b>Equity capital of a company</b>		5,189,837,000		4,370,119,000		3,770,004,000
<b>Cash and cash equivalents</b>	3,213,376,000		2,951,422,000		2,057,440,000	
<b>Accrued liabilities</b>		173,578,000		184,462,000		206,994,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		1,240,379,000		1,157,077,000		854,308,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		392,105,000		356,350,000		349,418,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		134,867,000		85,134,000		54,806,000
<b>Total assets</b>	6,822,321,000	6,822,321,000	5,883,546,000	5,883,546,000	4,973,730,000	4,973,730,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	2,524	2,324	2,094
<b>Equity ratio</b>	76.07%	74.28%	75.80%
<b>Debt-equity ratio</b>	31.46%	34.63%	31.93%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	28.36%	35.62%	-66.29%

**Income statement**

	<b>2023</b>	<b>2022</b>	<b>2021</b>
<b>Turnover</b>	3,695,649,000	3,394,635,000	2,986,267,000
<b>Net income</b>	597,599,000	340,660,000	948,581,000
<b>EBIT</b>	769,992,073	489,345,796	526,678,310
<b>Operating income before taxes</b>	834,215,000	529,116,000	570,444,000
<b>Cash Flow</b>	496,487,000	969,941,000	749,488,000
<b>Net interest income</b>	-2,551,000	-2,666,000	-1,908,000
<b>Research and development expenses</b>	1,627,594,000	1,585,936,000	1,458,179,000
<b>Income taxes</b>	236,616,000	188,456,000	-378,137,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	1,347,360	1,344,124	1,312,303

**Board of Directors**
**Members of Management Board**

Edmund Harrigan	Member of Board of Directors
Jacquelyn Fouse	Member of Board of Directors
Katherine High	Member of Board of Directors
Otis Brawley	Member of Board of Directors
Susanne Antonie Schaffert	Member of Board of Directors
Jean-Jacques Bienaimé	Member of Board of Directors
Julian Baker	Member of Board of Directors
Paul Clancy	Member of Board of Directors
Hervé Hoppenot	Chairman of Managing Board
Barry P. Flannelly	Member of Executive Committee
Lothar H. Finke	Member of Executive Committee
Steven H. Stein	Member of Executive Committee
Christiana Stamoulis	Member of Executive Committee
Denise Brashear	Member of Executive Committee
Jonathan E. Dickinson	Member of Executive Committee
Michael Morrissey	Member of Executive Committee
Pablo J. Cagnoni	Member of Executive Committee
Paula J. Swain	Member of Executive Committee
Sheila A. Denton	Member of Executive Committee
Vijay Iyengar	Member of Executive Committee
Xiaozhao Wang	Member of Executive Committee